Frontage Laboratories, Inc., a global contract research organization, announces the acquisition of Concord Biosciences, formerly known as Ricerca Biosciences, LLC, a preclinical CRO located near Cleveland, Ohio. Founded in 1986, Concord Bio supports the pharmaceutical, agricultural, chemical, and animal health industries with drug safety, metabolism, bioanalytical, residue, and environmental fate studies.

Dr. Song Li, Founder and CEO of Frontage Laboratories, said, “We have committed to build a global CRO company with integrated services. The acquisition of Concord Biosciences is a significant step toward reaching our goal. The addition of Concord Bio to the Frontage family will enable us to provide pharmaceutical product development services from lead selection to IND-enabling studies to commercialization. Additionally, the agrochemical expertise of Concord Bio will position Frontage as a major CRO in the agricultural products industry.”.

Frontage Laboratories, Inc., a full-service early-stage CRO with locations in the USA and China, has been assisting global biopharmaceutical organizations in their drug development efforts since 2001.

Founded in 1986, Concord is a contract research organization that supports the pharmaceutical, agricultural, and animal health industries.